moatshark My

All holdings

Charles River Laboratories International

CRL

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
2
In their latest 13F (Q3 2026)
See who
Value held
$510m
Combined value at quarter end
Last quarter
1 bought
1 sold or trimmed
Price at Q2 ’26 end
$226.79
+31.5% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

-4.7%Q3 ’24
-6.3%Q4 ’24
-18.5%Q1 ’25
+0.8%Q2 ’25
+3.1%Q3 ’25
+27.5%Q4 ’25
-13.5%Q1 ’26
+31.5%Q2 ’26
Q3 ’24: -4.7%; Q4 ’24: -6.3%; Q1 ’25: -18.5%; Q2 ’25: +0.8%; Q3 ’25: +3.1%; Q4 ’25: +27.5%; Q1 ’26: -13.5%; Q2 ’26: +31.5%

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

3Q4 ’23
3Q1 ’24
3Q2 ’24
3Q3 ’24
2Q4 ’24
1Q1 ’25
2Q2 ’25
2Q3 ’25
2Q4 ’25
2Q1 ’26
2Q2 ’26
0Q3 ’26
Q4 ’23: 3; Q1 ’24: 3; Q2 ’24: 3; Q3 ’24: 3; Q4 ’24: 2; Q1 ’25: 1; Q2 ’25: 2; Q3 ’25: 2; Q4 ’25: 2; Q1 ’26: 2; Q2 ’26: 2; Q3 ’26: 0

Counts the managers on this site whose 13F for that quarter includes Charles River Laboratories International.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Charles River Laboratories International
Harris Associates (Oakmark)0.7%$508m$508mAdded +4.1%5 qtrs
Horizon Kinetics0.0%$1.6m$1.6mTrimmed -42%26 qtrs

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works
From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Insider purchases and sales of Charles River Laboratories International
Bought or soldFiling
5 Oct 2026Parisotto Shannon MCEVP, Disc & Safety Assessment▼ Sold981$308.44$303kForm 4
30 Sep 2026Coleman GlennEVP & Chief Financial Officer▲ Bought10$297.43$3kForm 4
25 Aug 2026Foster James CDirector▼ Sold33,561$300.00$10.1mForm 4
19 Aug 2026Parisotto Shannon MCEVP, Disc & Safety Assessment▼ Sold2,039$294.12$600kForm 4
18 Aug 2026Andrews Nancy CDirector▼ Sold573$285.24$163kForm 4
11 Aug 2026Girshick BirgitChief Executive Officer▼ Sold6,500$279.90$1.8mForm 4
11 Aug 2026Parisotto Shannon MCEVP, Disc & Safety Assessment▼ Sold3,714$279.66$1.0mForm 4
10 Aug 2026Foster James CDirector▼ Sold28,733$275.00$7.9mForm 4
6 Aug 2026Creamer Victoria LEVP & Chief People Officer▼ Sold4,179$259.16$1.1mForm 4
6 Aug 2026Knell Michael GunnarSVP, Finance and CAO▼ Sold1,274$259.07$330kForm 4
6 Aug 2026Knell Michael GunnarSVP, Finance and CAO▼ Sold1,205$258.53$312kForm 4
6 Aug 2026Knell Michael GunnarSVP, Finance and CAO▼ Sold901$260.63$235kForm 4
6 Aug 2026Knell Michael GunnarSVP, Finance and CAO▼ Sold810$261.45$212kForm 4
6 Aug 2026Knell Michael GunnarSVP, Finance and CAO▼ Sold736$258.53$190kForm 4
6 Aug 2026Knell Michael GunnarSVP, Finance and CAO▼ Sold620$263.94$164kForm 4
6 Aug 2026Knell Michael GunnarSVP, Finance and CAO▼ Sold482$265.17$128kForm 4
6 Aug 2026Knell Michael GunnarSVP, Finance and CAO▼ Sold404$258.53$104kForm 4
6 Aug 2026Knell Michael GunnarSVP, Finance and CAO▼ Sold213$262.37$56kForm 4
5 Aug 2026Parisotto Shannon MCEVP, Disc & Safety Assessment▼ Sold5,046$263.00$1.3mForm 4

About the company

Sector
Health care · Services-Commercial Physical & Biological Research
Financial year ends
27 December
Shares outstanding
48m at 25 Jul 2026
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

$1.2bn2013
$1.4bn2015
$1.9bn2017
$2.6bn2019
$3.5bn2021
$4.1bn2023
$4.0bn2025
2013: $1.2bn; 2014: $1.3bn; 2015: $1.4bn; 2016: $1.7bn; 2017: $1.9bn; 2018: $2.3bn; 2019: $2.6bn; 2020: $2.9bn; 2021: $3.5bn; 2022: $4.0bn; 2023: $4.1bn; 2024: $4.0bn; 2025: $4.0bn
Charles River Laboratories International revenue and net income by year
YearRevenueNet income
2025$4.0bn−$144m
2024$4.0bn$22.2m
2023$4.1bn$475m
2022$4.0bn$486m
2021$3.5bn$391m
2020$2.9bn$364m
2019$2.6bn$252m
2018$2.3bn$226m
2017$1.9bn$123m
2016$1.7bn$155m
2015$1.4bn$149m
2014$1.3bn$127m
2013$1.2bn$103m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.